121702-59-8

Upstream product

• 1136-86-3 methyl (3,4,5-trimethoxyphenyl) ketone 
• 5438-36-8 5-iodovaniline 
• 116681-62-0 4-Hydroxy-4-(3-methanesulfonyl-5-methoxy-4-propoxy-phenyl)-1-(3,4,5-trimethoxy-phenyl)-butan-1-one 
• 116681-64-2 (S)-4-Hydroxy-4-(3-methanesulfonyl-5-methoxy-4-propoxy-phenyl)-1-(3,4,5-trimethoxy-phenyl)-butan-1-one 
• 113790-67-3 1-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanedione 
• 116681-60-8 (1R,4RS)-1-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-4-(3,4,5-trimethoxyphenyl)butane-1,4-diol 
• 116681-60-8 1-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanediol 

Downstream Products

• 129314-27-8 trans-2-(3-methoxy-5-methylsulfonyl-4-n-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran 

Relevant academic research and scientific papers

ENANTIOSELECTIVE CYCLIZATION OF CHIRAL BUTANE-1,4-DIOLS TO CHIRAL TETRAHYDROFURANS: SYNTHESIS OF CHIRAL TRANS-2-(3-METHOXY-5-METHYLSULFONYL-4-PROPOXYPHENYL-5-(3,4,5-TRIMETHOXYPHENYL)TETRAHYDROFURAN (L-659,989), A POTENT PAF-RECEPTOR ANTAGONIST

Acid catalyzed cyclization of (1R,4RS)- and(1S,4RS)-1-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-4-(3,4,5-trimethoxyphenyl)butane-1,4-diols to the corresponding chiral cis- and trans-tetrahydrofurans proceeds with retention of configuration at C-1.Using